Taysha Gene Therapies Disclosed That It Has Commenced An Underwritten Public Offering Of Up To $75M Of Shares Of Its Common Stock And, In Lieu Of Common Stock To Certain Investors That So Choose, Pre-funded Warrants To Purchase Shares Of Its Common Stock
Taysha Gene Therapies Disclosed That It Has Commenced An Underwritten Public Offering Of Up To $75M Of Shares Of Its Common Stock And, In Lieu Of Common Stock To Certain Investors That So Choose, Pre-funded Warrants To Purchase Shares Of Its Common Stock
Taysha基因治療公司披露，已開始發起不超過7500萬美元的普通股股票的擔保公開發行，並向某些選擇的投資者提供預融資認股權以購買其普通股。
Taysha Gene Therapies Disclosed That It Has Commenced An Underwritten Public Offering Of Up To $75M Of Shares Of Its Common Stock And, In Lieu Of Common Stock To Certain Investors That So Choose, Pre-funded Warrants To Purchase Shares Of Its Common Stock
Taysha基因治療公司披露，已開始發起不超過7500萬美元的普通股股票的擔保公開發行，並向某些選擇的投資者提供預融資認股權以購買其普通股。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。